Sun Pharmaceutical Industries Ltd. isn’t writing off potential opportunities, at least not yet, for a higher dose version of deuruxolitinib, its oral selective inhibitor of JAK1/2 currently filed in a lower dose strength with the US Food and Drug Administration.
Sun Specialty Basket Rx Trends Up, Not Giving Up On Higher Dose Deuruxolitinib
Sun Pharma sees all time high market share and prescription trends in the US for key specialty products and remains upbeat on the prospects of deuruxolitinib for alopecia areata. The company also isn’t ruling out a potential comeback, at least not yet, for a higher dose version of the JAK1/2 inhibitor.
More from Business
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.